Hetero Labs Limited Unit V FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection VAI · Aug 12, 2022
  • 1 Class I recall
  • Last warning letter 2017
Inspections 5 1 OAI
Recalls 11 1 Class I (9%)
Warning letters 1 Latest Aug 15, 2017
510(k) clearances 0 None on file

Hetero Labs Limited Unit V has 11 FDA recalls (1 Class I), 5 inspections, 0 510(k) clearances and 1 compliance action on record. FDA has issued 1 warning letter to Hetero Labs Limited Unit V, the most recent on Aug 15, 2017.

What these totals cover: FDA records filed under the name "Hetero Labs Limited Unit V" and its spelling variant "Hetero Labs Limited (Unit V)".

Latest recall
D-0484-2026 · Class II · Mar 26, 2026
Latest inspection
Aug 12, 2022 · VAI

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls11 (1 Class I)Nov 15, 2026File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections5Nov 17, 2026Newest record Nov 9, 2026Current
Compliance actions1Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

Hetero Labs Limited Unit V's FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

Hetero Labs Limited Unit V: FDA inspections per year

2017: 0 inspections (0 OAI), 1 warning letter, 1 recall record (0 Class I) 2018: 0 inspections (0 OAI), 0 warning letters, 8 recall records (1 Class I) 2019: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2022: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2024: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2025: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2026: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202600010
202500000
202400000
202300000
202210000
202100000
202000010
201900000
201800081
201700110

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing Hetero Labs Limited Unit V as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Hetero Labs Limited Unit V yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Hetero Labs Limited Unit V FDA Warning Letters

1 warning letter on Aug 15, 2017.

IssuedSubjectIssuing officeClose-out letter
Aug 15, 2017 · Record page

A warning letter is FDA's formal notice that a company has violated FDA requirements. Each date links to the letter on fda.gov where FDA has it online. Search the text of every letter with the FDA warning letter search.

Recent recalls

11 recall records from Dec 22, 2017 to Mar 26, 2026.

NumberClassProductDate
D-0484-2026Class IIPantoprazole Sodium, Delayed-Release Tablets, USP, 40 mg, 1000-count bottle, Rx only, Manufactured…Mar 26, 2026
D-1545-2020Class IILosartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber…Aug 6, 2020
D-1213-2018Class IIMontelukast Sodium Tablets, 10 mg*, 30-count bottles, Rx Only, By: Hetero, Hetero Labs Limited…Aug 20, 2018
D-0081-2019Class IMontelukast Sodium Tablets 10 mg, 30-count bottle, Rx Only, By: Hetero Hetero Labs Limited, Unit V…Aug 15, 2018
D-1114-2018Class IICamber Pharmaceuticals, Inc. Valsartan Tablets, USP, 80 mg, 90 count bottles, Rx Only Manufactured…Aug 8, 2018
D-1113-2018Class IICamber Pharmaceuticals, Inc. Valsartan Tablets, USP, 40 mg, 30 Tablets Rx Only Manufactured for…Aug 8, 2018
D-1116-2018Class IICamber Pharmaceuticals, Inc. Valsartan Tablets, USP, 320 mg, 90 tablets, Rx Only Manufactured for…Aug 8, 2018
D-1115-2018Class IICamber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only Manufactured for…Aug 8, 2018
D-0602-2018Class IIValacyclovir Tablets USP 1 gram, 30-count bottle, Rx Only, Manufactured for Camber Pharmaceuticals…Feb 13, 2018
D-0601-2018Class IIValganciclovir Tablets, USP, 450 mg, 60-count bottle, Rx Only, Manufactured for Camber…Feb 13, 2018
D-0415-2018Class IIFamciclovir Tablets, 500 mg, 30-count bottles, Rx Only, Manufactured For: Camber Pharmaceuticals…Dec 22, 2017

Recent FDA inspections

5 inspections from Nov 19, 2010 to Aug 12, 2022.

DateSiteProductClassificationFEI
Aug 12, 2022Mahabubnagar, IndiaDrugsVoluntary Action Indicated (VAI)3008307735
Dec 16, 2016Mahabubnagar, IndiaDrugsOfficial Action Indicated (OAI)3008307735
May 1, 2015Mahabubnagar, IndiaDrugsNo Action Indicated (NAI)3008307735
May 24, 2013Mahabubnagar, IndiaDrugsVoluntary Action Indicated (VAI)3008307735
Nov 19, 2010Mahabubnagar, IndiaDrugsNo Action Indicated (NAI)3008307735
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

Compliance Actions

FDA's compliance actions data lists 1 compliance action under Hetero Labs Limited Unit V: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.

Most recent: Warning Letter, Aug 15, 2017.

The warning letters in this data are listed above, together with the letters FDA posts online; a letter found in both is shown once. Other actions are not listed on this page. Search them with the FDA warning letter search or browse all compliance actions.

FDA-inspected facilities

1 inspected site, newest inspection first.

FacilityLocationInspectionsLatest
FEI 3008307735Mahabubnagar, India5Aug 12, 2022

Hetero Labs Limited Unit V and the FDA: common questions

Has Hetero Labs Limited Unit V received an FDA warning letter?

Yes. FDA has issued 1 warning letter to Hetero Labs Limited Unit V. The most recent is dated Aug 15, 2017.

Has Hetero Labs Limited Unit V received an FDA Form 483?

FDA has not published a Form 483 for "Hetero Labs Limited Unit V" in its reading room. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect Hetero Labs Limited Unit V?

The most recent FDA inspection on file ended Aug 12, 2022 at Mahabubnagar, India and was classified VAI. FDA has 5 inspections of Hetero Labs Limited Unit V on file, 1 of them classified OAI (official action indicated).

Has Hetero Labs Limited Unit V had an FDA recall?

Yes. Hetero Labs Limited Unit V has 11 FDA recalls on record, 1 of them Class I, the most serious class. The most recent started Mar 26, 2026.

Need more than this page shows? Ask about Hetero Labs Limited Unit V in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.